Anemia is the most common hematologic abnormality in patients with chronic renal failure.
The reasons for anemia in chronic renal failure are many and include erythropoietin and iron …

Iron deficiency frequently complicates both acute and chronic phases of recombinant human
erythropoietin (r-HuEPO; EPOGEN [epoetin alfa], AMGEN Inc, Thousand Oaks, CA) therapy …

Anemia prevention for hemodialysis relies primarily on supplemental erythropoietin (EPO)
and intravenous iron (IV-iron). The doses of EPO utilized are somewhat higher than normal …

The management of anemia in dialysis patients involves a comprehensive understanding of
the role of erythropoietin deficiency and of the importance of adequate available iron. It is …

An adequate supply of bioavailable iron is crucial for an optimal response to recombinant
human erythropoietin (EPO)[1, 2]. However, the amount of iron needed as the necessary …

. In haemodialysis patients, both the mean haemo- While 15.3–21.7% of haemodialysis
patients were clasglobin levels and the epoetin dose required to sified as having absolute …

This study was performed to evaluate the attitude of the physicians in Saudi Arabia towards
iron supplementation in hemodialysis patients treated by recombinant human erythropoietin …

Administration of intravenous iron to supplement erythropoiesis stimulating agents (ESAs)
has become a common practice in the management of anemia in patients with end-stage …

Despite the proven benefits of intravenous (iv) iron therapy in anemia management, it
remains underutilized in the hemodialysis population. Although overall iv iron usage …

The cornerstone of anemia management in hemodialysis (HD) involves the administration of
iron and erythropoietin stimulating agents (ESAs) to minimize transfusions and improve …